The Service I received from the Orders and Customer Service Team was very professional. Their responses were very quick and actioned on immediately.

Mr Gueorgui TzvetanovSenior ManagerERGO Austria International AG

The Research and Markets’ customer support team provided me with timely and immediate responses and delivered exactly the information that I was looking for – great job. Thank you very much. I would recommend them to anybody who is looking for market research data.

Great customer service and super responsive. I was having issues with my payment method but Claire in customer service was super responsive to help several times until the issue was entirely resolved. Great job

Mr Detlef RethagePresidentNitto Avecia Inc

The reports ordered are of good quality and are relevant to our business needs.

Mr Etienne AdriansenSenior Director Business EvaluationLEO Pharma

Thank you for all of your help! I think your service is excellent. It is an easy platform to order interesting reports.

Mr Tomi AmberlaConsultantPöyry Management Consulting

The team at Research and Markets are first rate. Their market intelligence is relevant and accurate and the customer service fast, responsive and dependable. I always benefit from knowledge gained from their comprehensive studies and will continue to utilize their services.

Ms Liz DickinsonCEOPhysical Enterprises Inc

I have bought reports from other sources but the report that I bought from Research and Markets was the most detailed of the lot. Their customer service was excellent and I was able to get the report without any fuss.

Mr Naveed KamalAsst Manager: Business DevelopmentRangs Group Ltd

Celebrating 15
years in business
by partnering
with UNICEF for education

FEATURED COMPANIES

The global high potency active pharmaceutical ingredients (HPAPI) market is expected to reach USD 24.09 billion by 2021 from USD 16.02 billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021. This market is categorized on the basis of type, type of manufacturer, type of synthesis, therapeutic application, and region.

Major factors contributing to the growth of the high potency rapid growth in the oncology drugs market, increasing focus of pharmaceutical companies on HPAPIs, and advancements in HPAPI technologies. Growing demand for antibody drug conjugates also provide an impetus for the growth of this market. Their high specificity of action, has caused ACDs to gain significant attention, resulting in a noteworthy increase in the number of ADCs under development. Considering the growing opportunities in this market, many companies are making significant investments for the development of novel ACDs. In October 2015, ADC Biotechnology (U.K.) invested USD 10 million to build a manufacturing facility for advanced anticancer drugs. Many companies are also cross collaborating for research in the development of next-generation ADCs. For example, in June 2014, Merck Serono entered into a collaboration with Mersana Therapeutics Inc. for the development of next-generation ADCs.

Emerging markets have opened an array of opportunities for the high potency active pharmaceutical ingredients market. Moreover, the market also offers lucrative opportunities for CMOs and CDMOs. However, factors such as a stringent regulatory requirements and requirement of large investments may restrain the growth of this market.

Based on type, the market is segmented into innovative and generic HPAPIs. On the basis of type of manufacture, the HPAPIs market is categorized into two segments, captive manufacturer and merchant manufacturer. On the basis of type of synthesis, the HPAPIs market is segmented into synthetic HPAPIs and biotech HPAPIs. On the basis of therapeutic application, the HPAPIs market is further segmented into oncology, hormonal disorders, glaucoma, and other therapeutic applications.

Research Coverage:

Apart from the comprehensive geographical and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the active pharmaceutical ingredients market and their product portfolios, developments, and strategies. The above-mentioned market research data, current market size, and forecast of the future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, changes in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The Report Provides Insights on the Following Pointers:

Market Penetration: Comprehensive information on the product portfolios of top players in the active pharmaceutical ingredients market. The report analyzes the active pharmaceutical ingredients market by application, sales channel, and region

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the active pharmaceutical ingredients market

Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the active pharmaceutical ingredients market

FEATURED COMPANIES

The global active pharmaceutical ingredients market is expected to reach USD 24.09 Billion by 2021 from USD 16.02 Billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021.

Market growth is driven by the rapid growth in the oncology drugs market, growing demand for antibody drug conjugates, increasing focus of pharmaceutical companies on HPAPIs, and advancements in HPAPI technologies. Furthermore emerging markets and emerging technologies have opened an array of opportunities for the growth of the high potency active pharmaceutical ingredients market. The market also offers lucrative growth opportunities for CMO and CDMOs. However, factors such as stringent regulatory requirements and requirement of large investments may restrain the growth of this market. The active pharmaceutical ingredients market is segmented on the basis type, type of manufacturer, type of synthesis, therapeutic application, and region.

Based on type, the market is segmented into innovative and generic HPAPIs. The innovative HPAPIs segment is expected to account for the largest share in 2016. The large share of this segment is attributed to the presence of large number of patent-protected innovative HPAPIs, their higher price as compared to generics, growing focus of major players on the development of novel high-potency products, and the growing demand for high-potency cancer therapeutics. The generic HPAPIs segment is expected to register the highest growth rate in the forecast period. The impending patent cliff, increasing healthcare costs, and government initiatives to encourage the adoption of generics are the major factors driving the growth of this market segment.

On the basis of type of manufacture, the HPAPIs market is categorized into two segments, captive manufacturer and merchant manufacturer. In 2016, the captive manufacturers segment is estimated to account for the largest share. The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for their economic benefits. The merchant manufacturers segment is expected to register the highest CAGR during the forecast period. The high growth rate of the merchant manufacturers segment is attributed to the growing trend of outsourcing manufacturing processes.

On the basis of type of synthesis, the HPAPIs market is segmented into synthetic HPAPIs and biotech HPAPIs. The synthetic HPAPIs segment is estimated to command the largest share in 2016. The increasing emergence of new molecules in the market, rising number of new product approvals, technological advancements in synthesis, and ease of production are driving the growth of the synthetic HPAPIs segment. The biotech HPAPIs segment is expected to grow at the highest CAGR during the forecast period. Advances in biotechnology, growing demand for antibody drug conjugates, growing demand due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies are the major factors driving the growth of this market.

On the basis of therapeutic application, the HPAPIs market is further segmented into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. The oncology segment is estimated to account for the largest share of the global HPAPIs market in 2016. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this application segment

The global high potency active pharmaceutical ingredients market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to lead the global active pharmaceutical ingredients market in the forecast period. Over the next five years, Asia Is expected to register highest growth rate. Factors such as high prevalence of cancer and other lifestyle- and age-related diseases, increase in disposable income, and growing market for merchant manufacturers in this region owing to the low labor and manufacturing costs are driving the growth of the Asian HPAPIs market